ACRSTwo shots on goal
Aclaris came out swinging with a pair of pipeline updates: ATI-052, its anti-TSLP/IL-4Rα bispecific antibody, delivered positive full top-line results in a Phase 1a healthy-volunteer trial, and ATI-2138 now has lichen planus as its lead indication.
Why ATI-052 matters
This is the kind of update biotech investors love because it’s not just “we’re still working on it.” The company says ATI-052 exceeded its target profile, showed an estimated half-life of about 45 days, and could support dosing every three months. That’s the sweet spot: more durability, more convenience, and potentially a better shot at standing out in Th2-driven diseases like asthma and atopic dermatitis.
The next readout is the real test
The plot doesn’t end here. Enrollment and dosing are already underway in Phase 1b studies in asthma and atopic dermatitis, with top-line results expected in the second half of 2026. Translation: today’s news is a promising trailer, not the full movie.
ATI-2138 gets a new spotlight
On the small-molecule side, Aclaris picked lichen planus as the lead indication for ATI-2138, which it says is designed to address both root inflammation and symptoms. That gives the program a clearer path forward, and investors usually like anything that takes a foggy pipeline and turns it into something with a lane.
Big picture: Aclaris is trying to prove it has more than one scientific story to tell, and today’s update gives the stock a little more to work with than pure hope and lab coats.